The value of endothelin receptor type B promoter methylation as a biomarker for the risk assessment and diagnosis of prostate cancer: A meta-analysis |
| |
| Affiliation: | 1. Paul Strickland Scanner Centre, Mount Vernon Cancer Centre, Middlesex, UK;2. Division of Radiology, IEO - European Institute of Oncology, Milan, Italy;3. Northampton General Hospital, NHS Trust, Northampton, UK;4. King''s College Hospital, NHS Foundation Trust, London, UK;1. Department of Thoracic Surgery, The Second People’s Hospital of Nantong, Nantong, Jiangsu, China;2. Department of Radiation Oncology, Nantong Tumor Hospital, Nantong, Jiangsu, China;1. Department of Urology, The Johns Hopkins University School of Medicine, The James Brady Urological Institute, Johns Hopkins Hospital, Baltimore, Maryland;2. Department of Pathology, The Johns Hopkins University School of Medicine, The James Brady Urological Institute, Johns Hopkins Hospital, Baltimore, Maryland;1. Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai 200032, PR China;2. Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, PR China;3. Institute of Pathology, Fudan University, Shanghai 200032, PR China;1. Department of Neurosurgery, The Third Affiliated Hospital of Chongqing Medical University (Gener Hospital), PR China;2. Department of Neurosurgery, The Affiliated Huai’an Hospital of Xuzhou Medical University and The Second People’s Hospital of Huai’an, PR China |
| |
| Abstract: | Previous researches have demonstrated that the methylation status of the EDNRB promoter was associated with the prostate cancer (PCa), but these conclusions remained controversial. Thus, the aim of this meta-analysis was to evaluate the association between EDNRB promoter methylation and the PCa. According to the PRISMA statement, the Web of Science, PubMed, EMBASE, and Cochrane Library databases were retrieved. The ORs and 95 % CIs were analyzed to evaluate the associations between EDNRB promoter methylation and the risk and clinical features of PCa. Heterogeneity among the included studies was estimated by I2 statistic and Q test. Publication bias and sensitivity analysis were utilized to test the robustness of our outcomes. In addition, the pooled sensitivity and specificity were calculated to assess the diagnostic value of EDNRB methylation for PCa. Ultimately, 11 eligible studies were included. Under the random-effects model, the pooled OR shown that the frequency of EDNRB methylation was substantially higher in cases compared with controls (OR = 5.42, 95 % CI = 1.98–14.88, P = 0.001). The similar results were also found by the data from TCGA database. Subgroup analysis according to the methylation detection method showed that the heterogeneity in quantitative methylation-specific polymerase chain reaction (qMSP) group was insignificant (I2 = 0.0 %, P = 0.669). Moreover, the pooled sensitivity for all-inclusive studies was 0.55 (95 % CI: 0.26-0.81), and the pooled specificity was 0.93 (95 % CI: 0.55-0.99). The methylation of EDNRB promoter might increase the risk of PCa. Meanwhile, EDNRB promoter methylation test combined with PSA testing and/or other biomarkers could be promising diagnostic biomarkers for more accurate detection of PCa. |
| |
| Keywords: | Prostate cancer EDNRB methylation Risk Diagnosis Meta-analysis |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
